# US 2021/0277045 A1 · Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277045 A1
- Document ID: US20210277045A1
- Status: Published application
- Kind: A1
- Application number: 17/306,659
- Filed: 2021-05-03
- Published: 2021-09-09
- Earliest claimed: 2017-02-01
- Assignees: Atea Pharmaceuticals, Inc.
- Applicants: Atea Pharmaceuticals, Inc.
- Inventors: Adel Moussa; Jean-Pierre Sommadossi
- Web page: https://patentgrep.com/patent/US20210277045A1

## CPC

- C07H 19/20: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 31/708: having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- C07H 1/00: Processes for the preparation of sugar derivatives
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

A hemi-sulfate salt of the structure: to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.

## Claims

### Claim 1

A pharmaceutical composition comprising an effective amount of a compound of the formula:
and an effective amount of an additional anti-viral compound selected from a protease inhibitor, a NS5B polymerase inhibitor, and a NS5A inhibitor in a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1 comprising a compound of the formula:

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1 comprising a compound of the formula:

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the additional anti-viral compound is a protease inhibitor.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the protease inhibitor is a NS3/4A protease inhibitor

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the additional anti-viral compound is a NS5A inhibitor.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the additional anti-viral compound is a NS5B polymerase inhibitor.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, in an oral dosage form.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the oral dosage form is a solid dosage form.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the solid dosage form is a tablet or capsule.

### Claim 11 (depends on 8)

The pharmaceutical composition of claim 8, wherein the oral dosage form is a liquid dosage form.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the liquid dosage form is a suspension or solution.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, in an intravenous formulation.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, in a parenteral formulation.

### Claim 15 (depends on 2)

The pharmaceutical composition of claim 2, wherein the additional anti-viral compound is a protease inhibitor.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein the protease inhibitor is a NS3/4A protease inhibitor

### Claim 17 (depends on 2)

The pharmaceutical composition of claim 2, wherein the additional anti-viral compound is a NS5A inhibitor.

### Claim 18 (depends on 2)

The pharmaceutical composition of claim 2, wherein the additional anti-viral compound is a NS5B polymerase inhibitor.

### Claim 19 (depends on 2)

The pharmaceutical composition of claim 2, in an oral dosage form.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the oral dosage form is a solid dosage form.

### Claim 21 (depends on 20)

The pharmaceutical composition of claim 20, wherein the solid dosage form is a tablet or capsule.

### Claim 22 (depends on 19)

The pharmaceutical composition of claim 19, wherein the oral dosage form is a liquid dosage form.

### Claim 23 (depends on 22)

The pharmaceutical composition of claim 22, wherein the liquid dosage form is a suspension or solution.

### Claim 24 (depends on 2)

The pharmaceutical composition of claim 2, in an intravenous formulation.

### Claim 25 (depends on 2)

The pharmaceutical composition of claim 2, in a parenteral formulation.

### Claim 26 (depends on 3)

The pharmaceutical composition of claim 3, wherein the additional anti-viral compound is a protease inhibitor.

### Claim 27 (depends on 26)

The pharmaceutical composition of claim 26, wherein the protease inhibitor is a NS3/4A protease inhibitor

### Claim 28 (depends on 3)

The pharmaceutical composition of claim 3, wherein the additional anti-viral compound is a NS5A inhibitor.

### Claim 29 (depends on 3)

The pharmaceutical composition of claim 3, wherein the additional anti-viral compound is a NS5B polymerase inhibitor.

### Claim 30 (depends on 3)

The pharmaceutical composition of claim 3, in an oral dosage form.

### Claim 31 (depends on 30)

The pharmaceutical composition of claim 30, wherein the oral dosage form is a solid dosage form.

### Claim 32 (depends on 31)

The pharmaceutical composition of claim 31, wherein the solid dosage form is a tablet or capsule.

### Claim 33 (depends on 30)

The pharmaceutical composition of claim 30, wherein the oral dosage form is a liquid dosage form.

### Claim 34 (depends on 33)

The pharmaceutical composition of claim 33, wherein the liquid dosage form is a suspension or solution.

### Claim 35 (depends on 3)

The pharmaceutical composition of claim 3, in an intravenous formulation.

### Claim 36 (depends on 3)

The pharmaceutical composition of claim 3, in a parenteral formulation.